Prime Medicine Patents

Patent portfolio assigned to Prime Medicine (verified via public assignee records). Estimated patent count: 5. Prime Medicine is a clinical-stage gene-editing biotech (prime editing; NASDAQ:PRME). Competitors Beam Therapeutics, Intellia, CRISPR Therapeutics, Editas from STAT News and equity analysis. No notable_customers: pre-revenue therapeutics developer. has_patents=true: Prime Medicine, Inc. is the assignee on multiple Google Patents results including WO2024238825A1 (B2M-targeting genome editing), WO2024119098A1 (LNP delivery), WO2023015014A1 (myotonic dystrophy), US20240376466A1 (Fanconi anemia); count is a visible-minimum estimate, actual portfolio is larger.